Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients

Citations Over TimeTop 10% of 2022 papers

Abstract

Our study showed that skin-oriented toxicities do not share a single pattern and are related to several factors, including the specific agent administered and the underlying malignancy treated. Follow-up plans should be individualized in order to minimize the risk for severe reactions that could compromise optimum therapeutic outcome. What is already known about this topic? Patients with cancer treated with different immune checkpoint inhibitors (ICIs) carry an increased risk of developing various types of skin toxicities. What are the clinical implications of this work? In this multicentre cohort study we showed that ICI-related skin toxicities do not share a single pattern and may depend on several factors, including the specific agent administered and the underlying malignancy. Among patients with macular rash, vitiligo or multiple skin toxicities, patients received ICIs more frequently for melanoma than for non-small cell lung cancer. The combination of ICI and chemotherapy compared with ICI monotherapy occurred to a lesser extent in patients with psoriatic rash lichenoid and eczematous reactions, compared with patients with pruritus. Clinical awareness and specialized dermatological consultation should be advocated.

Related Papers

• → Prevalence of vitiligo among type 2 diabetic patients in an Iranian population(2013)24 cited
• → VITILIGO IN MATURE-ONSET DIABETES MELLITUS(1968)79 cited
• → Treatment of Vitiligo with Oral Corticosteroids(1976)43 cited
• Clinical Analysis on 2 008 Cases of Vitiligo(2002)
• → 26957 A study of dermoscopic features in relation to vitiligo activity(2021)